Novo Nordisk (NVO.US) oral form of Wegovy weight loss drug received acceptance of application by the United States FDA.

According to the Caijing APP, Danish pharmaceutical giant Novo Nordisk (NVO.US) stated that the U.S. Food and Drug Administration (FDA) has formally accepted its application for the launch of its oral weight loss drug Wegovy, and a decision will be made in the fourth quarter.